Allyx Therapeutics

Allyx Therapeutics is a biotech startup focused on developing groundbreaking therapies to preserve and protect synapses for individuals suffering from neurodegenerative diseases. The company’s lead compound, ALX 001, is a first-in-class oral therapy that targets the mGluR5 receptor, a critical component in preventing amyloid beta-induced neuronal damage. Founded in 2019 by Yale scientists, biopharma industry veterans, and venture capitalists, Allyx Therapeutics operates in the neurodegenerative disease market, primarily serving patients and healthcare providers. The company is currently in the Series A funding stage and has successfully utilized both public and private non-dilutive funding sources, including grants from the National Institutes of Health (NIH). Allyx Therapeutics generates revenue through the development and eventual commercialization of its proprietary therapies. The company is actively engaged in clinical research, with ongoing Phase 1b trials for ALX 001, and aims to expand its pipeline to address additional neurodegenerative conditions.

Keywords: neurodegenerative, synapses, mGluR5, amyloid beta, oral therapy, Phase 1b, biotech startup, Yale scientists, NIH funding, Series A.